Antiagrégants, aspirine, infarctus du myocarde et décès coronaires en Haute-Garonne. [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]

Détails

ID Serval
serval:BIB_203B85B9EA34
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Antiagrégants, aspirine, infarctus du myocarde et décès coronaires en Haute-Garonne. [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]
Périodique
Archives Des Maladies Du Coeur et Des Vaisseaux
Auteur⸱e⸱s
Cambou J.P., Lablache-Combier B., Marques-Vidal P., Ruidavets J.B., Ferrières J., Branchu M.P., Richard J.L.
ISSN
0003-9683 (Print)
ISSN-L
0003-9683
Statut éditorial
Publié
Date de publication
1995
Peer-reviewed
Oui
Volume
88
Numéro
4
Pages
459-463
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
The aim of this study was to determine changes in treatment of myocardial infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, to assess the role of aspirin and antiaggregant therapy. The cases of 416 patients admitted to hospital for myocardial infarction in 1986 and 1989 were reviewed. During this period the prescription of acetylsalicyclic acid during the acute phase of myocardial infarction increased threefold (26.4 vs 72.9%; p < 0.001) and fivefold when associated with fibrinolytics, coronary bypass or angioplasty. Similarly, the prescription of aspirin at the time of hospital discharge doubled (from 32.6 to 69.5%; p < 0.001). The dosage of aspirin decreased from 500 mg and more per day in 1986 to a dosage of 250 mg or 100 mg per day in 1989. The most commonly prescribed preparation is lysine acetylsalicylate. The hospital mortality in the Haute-Garonne between 1985 and 1989 has decreased as observed in the Haute-garonne centre of the MONICA project. During the same period, the prescription of aspirin in association with angioplasty, bypass surgery and fibrinolytics, has undergone a remarkable increase. The changes observed during this period of observation are in perfect accord with results already published of therapeutic trials of antithrombotic agents in the acute phase or the post-infarction period (ISIS 2).
Mots-clé
Aspirin/administration & dosage, Coronary Disease/epidemiology, Coronary Disease/mortality, Coronary Disease/therapy, France/epidemiology, Myocardial Infarction/epidemiology, Myocardial Infarction/mortality, Myocardial Infarction/therapy, Platelet Aggregation Inhibitors/administration & dosage
Pubmed
Web of science
Création de la notice
01/12/2016 16:02
Dernière modification de la notice
20/08/2019 13:56
Données d'usage